NEO
Neogenomics
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 3
Sell signal 0
consensus rating "Strong Buy"
Revenue Beats Expectation
EPS Beats Expectation
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About NEO
Neogenomics, Inc.
A leading provider of oncology testing and global contract research services
Life Science Tools and Services
10/29/1998
12/10/2012
NASDAQ Stock Exchange
2200
12-31
Common stock
9490 NeoGenomics Way, Fort Myers, Florida, 33912
--
Neogenomics, Inc., was incorporated in Nevada on October 29, 1988. Specializing in cancer genetics testing and information services, the company provides physicians with one of the most comprehensive oncology-centric testing menus in the world to help them diagnose and treat cancer. The Company's Drug Services Division provides clinical trials and drug development services to pharmaceutical clients. On October 29, 1998, the parent company was incorporated in Nevada as American Communications Enterprises, Inc., and the parent company changed its name to Neogenomics, Inc., on December 14, 2001.
Company Financials
EPS
NEO has released its 2024 Q4 earnings. EPS was reported at 0.04, versus the expected 0.03, beating expectations. The chart below visualizes how NEO has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
NEO has released its 2024 Q4 earnings report, with revenue of 172.00M, reflecting a YoY change of 10.57%, and net profit of -15.32M, showing a YoY change of -6.97%. The Sankey diagram below clearly presents NEO’s revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
